{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T00:54:03Z","timestamp":1759366443831,"version":"build-2065373602"},"reference-count":62,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["La Revue de M\u00e9decine Interne"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1016\/j.revmed.2017.07.005","type":"journal-article","created":{"date-parts":[[2017,9,23]],"date-time":"2017-09-23T00:45:49Z","timestamp":1506127549000},"page":"833-839","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Syndromes h\u00e9molytiques et ur\u00e9miques (SHU) et syndromes de microangiopathie thrombotique apparent\u00e9s\u00a0: traitement et pronostic"],"prefix":"10.1016","volume":"38","author":[{"given":"C.","family":"Rafat","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Coppo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Fakhouri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Fr\u00e9meaux-Bacchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Loirat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Zuber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Rondeau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.revmed.2017.07.005_bib0315","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1007\/s00467-008-0935-6","article-title":"Treatment and outcome of Shiga-toxin-associated hemolytic uremic syndrome (HUS)","volume":"23","author":"Scheiring","year":"2008","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.revmed.2017.07.005_bib0320","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1007\/s00467-012-2383-6","article-title":"Long-term outcomes of Shiga toxin hemolytic uremic syndrome","volume":"28","author":"Spinale","year":"2013","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.revmed.2017.07.005_bib0325","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/S0022-3476(94)70001-X","article-title":"Spectrum of extrarenal involvement in postdiarrheal hemolytic-uremic syndrome","volume":"125","author":"Siegler","year":"1994","journal-title":"J Pediatr"},{"key":"10.1016\/j.revmed.2017.07.005_bib0330","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/j.jpeds.2014.12.064","article-title":"Postdiarrheal hemolytic uremic syndrome in United States children: clinical spectrum and predictors of in-hospital death","volume":"166","author":"Mody","year":"2015","journal-title":"J Pediatr"},{"key":"10.1016\/j.revmed.2017.07.005_bib0335","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1001\/jama.290.10.1360","article-title":"Long-term renal prognosis of diarrhea-associated hemolytic uremic syndrome: a systematic review, meta-analysis, and meta-regression","volume":"290","author":"Garg","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.revmed.2017.07.005_bib0340","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1093\/cid\/cis196","article-title":"Need for long-term follow-up in enterohemorrhagic Escherichia coli-associated hemolytic uremic syndrome due to late-emerging sequelae","volume":"54","author":"Rosales","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.revmed.2017.07.005_bib0345","doi-asserted-by":"crossref","first-page":"e96","DOI":"10.1086\/383474","article-title":"A pediatric cluster of Shigella dysenteriae serotype 1\u00a0diarrhea with hemolytic uremic syndrome in 2\u00a0families from France","volume":"38","author":"Houdouin","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.revmed.2017.07.005_bib0350","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1007\/s00467-008-0820-3","article-title":"Enterohaemorrhagic Escherichia coli and Shigella dysenteriae type 1-induced haemolytic uraemic syndrome","volume":"23","author":"Mark Taylor","year":"2008","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.revmed.2017.07.005_bib0355","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1097\/MOP.0b013e32835d7f2c","article-title":"Update on Streptococcus pneumoniae associated hemolytic uremic syndrome","volume":"25","author":"Spinale","year":"2013","journal-title":"Curr Opin Pediatr"},{"key":"10.1016\/j.revmed.2017.07.005_bib0360","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1007\/s00467-007-0518-y","article-title":"Streptococcus pneumoniae-associated hemolytic uremic syndrome","volume":"23","author":"Copelovitch","year":"2008","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.revmed.2017.07.005_bib0365","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1186\/s13023-014-0161-1","article-title":"Three new cases of late-onset cblC defect and review of the literature illustrating when to consider inborn errors of metabolism beyond infancy","volume":"9","author":"Huemer","year":"2014","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.revmed.2017.07.005_bib0370","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1136\/jnnp.2007.133025","article-title":"The adolescent and adult form of cobalamin C disease: clinical and molecular spectrum","volume":"79","author":"Thauvin-Robinet","year":"2008","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.revmed.2017.07.005_bib0375","doi-asserted-by":"crossref","first-page":"554","DOI":"10.2215\/CJN.04760512","article-title":"Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults","volume":"8","author":"Fremeaux-Bacchi","year":"2013","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.revmed.2017.07.005_bib0380","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1111\/j.1399-3046.2008.00910.x","article-title":"Hemolytic uremic syndrome recurrence after renal transplantation","volume":"12","author":"Loirat","year":"2008","journal-title":"Pediatr Transplant"},{"key":"10.1016\/j.revmed.2017.07.005_bib0385","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1111\/ajt.12077","article-title":"Complement genes strongly predict recurrence and graft outcome in adult renal transplant recipients with atypical hemolytic and uremic syndrome","volume":"13","author":"Le Quintrec","year":"2013","journal-title":"Am J Transplant"},{"key":"10.1016\/j.revmed.2017.07.005_bib0390","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.2215\/CJN.02210310","article-title":"Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype","volume":"5","author":"Noris","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.revmed.2017.07.005_bib0395","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/ng.2590","article-title":"Recessive mutations in DGKE cause atypical hemolytic-uremic syndrome","volume":"45","author":"Lemaire","year":"2013","journal-title":"Nat Genet"},{"key":"10.1016\/j.revmed.2017.07.005_bib0400","doi-asserted-by":"crossref","first-page":"50","DOI":"10.2215\/CJN.06440616","article-title":"Pathogenic variants in complement genes and risk of atypical hemolytic uremic syndrome relapse after eculizumab discontinuation","volume":"12","author":"Fakhouri","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.revmed.2017.07.005_bib0405","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1681\/ASN.2006080811","article-title":"Differential impact of complement mutations on clinical characteristics in atypical hemolytic uremic syndrome","volume":"18","author":"Sellier-Leclerc","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.revmed.2017.07.005_bib0410","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.molimm.2015.03.246","article-title":"Atypical aHUS: State of the art","volume":"67","author":"Nester","year":"2015","journal-title":"Mol Immunol"},{"issue":"Suppl.\u00a04","key":"10.1016\/j.revmed.2017.07.005_bib0415","doi-asserted-by":"crossref","first-page":"iv131","DOI":"10.1093\/ndt\/gfu235","article-title":"Novel aspects of atypical haemolytic uraemic syndrome and the role of eculizumab","volume":"29","author":"Verhave","year":"2014","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.revmed.2017.07.005_bib0420","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/ng.2622","article-title":"DGKE and atypical HUS","volume":"45","author":"Quaggin","year":"2013","journal-title":"Nat Genet"},{"key":"10.1016\/j.revmed.2017.07.005_bib0425","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1681\/ASN.2012090903","article-title":"DGKE variants cause a glomerular microangiopathy that mimics membranoproliferative GN","volume":"24","author":"Ozaltin","year":"2013","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.revmed.2017.07.005_bib0430","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.revmed.2015.10.354","article-title":"[Telemedicine in thrombotic microangiopathies: a way forward in rare diseases requiring emergency care]","volume":"37","author":"Coppo","year":"2016","journal-title":"Rev Med Interne"},{"key":"10.1016\/j.revmed.2017.07.005_bib0435","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/1750-1172-6-60","article-title":"Atypical hemolytic uremic syndrome","volume":"6","author":"Loirat","year":"2011","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.revmed.2017.07.005_bib0440","doi-asserted-by":"crossref","first-page":"S62","DOI":"10.1038\/ki.2008.624","article-title":"Treatment options for HUS secondary to Escherichia coli O157:H7","volume":"112","author":"Bitzan","year":"2009","journal-title":"Kidney Int Suppl"},{"key":"10.1016\/j.revmed.2017.07.005_bib0445","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s00467-014-2918-0","article-title":"Hemoconcentration: a major risk factor for neurological involvement in hemolytic uremic syndrome","volume":"30","author":"Ardissino","year":"2015","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.revmed.2017.07.005_bib0450","doi-asserted-by":"crossref","first-page":"e673","DOI":"10.1542\/peds.2004-2236","article-title":"Relative nephroprotection during Escherichia coli O157:H7\u00a0infections: association with intravenous volume expansion","volume":"115","author":"Ake","year":"2005","journal-title":"Pediatrics"},{"key":"10.1016\/j.revmed.2017.07.005_bib0455","doi-asserted-by":"crossref","first-page":"2440","DOI":"10.1093\/jac\/dkv162","article-title":"Antibiotic treatment of verocytotoxin-producing Escherichia coli (VTEC) infection: a systematic review and a proposal","volume":"70","author":"Agger","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.revmed.2017.07.005_bib0460","doi-asserted-by":"crossref","first-page":"3790","DOI":"10.1128\/AAC.01783-09","article-title":"Different classes of antibiotics differentially influence shiga toxin production","volume":"54","author":"McGannon","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.revmed.2017.07.005_bib0465","doi-asserted-by":"crossref","first-page":"3478","DOI":"10.1128\/AAC.46.11.3478-3483.2002","article-title":"Effects of azithromycin on shiga toxin production by Escherichia coli and subsequent host inflammatory response","volume":"46","author":"Ohara","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.revmed.2017.07.005_bib0470","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1111\/j.1365-2036.2006.03036.x","article-title":"Systematic review: are antibiotics detrimental or beneficial for the treatment of patients with Escherichia coli O157:H7\u00a0infection?","volume":"24","author":"Panos","year":"2006","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.revmed.2017.07.005_bib0475","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1056\/NEJM200006293422601","article-title":"The risk of the hemolytic-uremic syndrome after antibiotic treatment of Escherichia coli O157:H7\u00a0infections","volume":"342","author":"Wong","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.revmed.2017.07.005_bib0480","doi-asserted-by":"crossref","first-page":"e4565","DOI":"10.1136\/bmj.e4565","article-title":"Validation of treatment strategies for enterohaemorrhagic Escherichia coli O104:H4\u00a0induced haemolytic uraemic syndrome: case-control study","volume":"345","author":"Menne","year":"2012","journal-title":"BMJ"},{"key":"10.1016\/j.revmed.2017.07.005_bib0485","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1001\/jama.2012.264","article-title":"Association between azithromycin therapy and duration of bacterial shedding among patients with Shiga toxin-producing enteroaggregative Escherichia coli O104:H4","volume":"307","author":"Nitschke","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.revmed.2017.07.005_bib0490","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1086\/499236","article-title":"Low risk of hemolytic uremic syndrome after early effective antimicrobial therapy for Shigella dysenteriae type 1\u00a0infection in Bangladesh","volume":"42","author":"Bennish","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.revmed.2017.07.005_bib0495","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1016\/S0140-6736(99)01251-9","article-title":"Effectiveness of therapeutic plasma exchange in the 1996\u00a0Lanarkshire Escherichia coli O157:H7\u00a0outbreak","volume":"354","author":"Dundas","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.revmed.2017.07.005_bib0500","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1086\/322598","article-title":"The central Scotland Escherichia coli O157:H7\u00a0outbreak: risk factors for the hemolytic uremic syndrome and death among hospitalized patients","volume":"33","author":"Dundas","year":"2001","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.revmed.2017.07.005_bib0505","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/s00467-010-1719-3","article-title":"Efficacy of eculizumab in a patient with factor-H-associated atypical hemolytic uremic syndrome","volume":"26","author":"Lapeyraque","year":"2011","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.revmed.2017.07.005_bib0510","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1093\/ndt\/gft470","article-title":"Outbreak of Escherichia coli O104:H4\u00a0haemolytic uraemic syndrome in France: outcome with eculizumab","volume":"29","author":"Delmas","year":"2014","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.revmed.2017.07.005_bib0515","doi-asserted-by":"crossref","first-page":"3807","DOI":"10.1093\/ndt\/gfs394","article-title":"Best supportive care and therapeutic plasma exchange with or without eculizumab in Shiga-toxin-producing E.\u00a0coli O104:H4\u00a0induced haemolytic-uraemic syndrome: an analysis of the German STEC-HUS registry","volume":"27","author":"Kielstein","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.revmed.2017.07.005_bib0520","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s00467-003-1382-z","article-title":"Pneumococcus-induced T-antigen activation in hemolytic uremic syndrome and anemia","volume":"19","author":"Cochran","year":"2004","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.revmed.2017.07.005_bib0525","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s00467-015-3076-8","article-title":"An international consensus approach to the management of atypical hemolytic uremic syndrome in children","volume":"31","author":"Loirat","year":"2016","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.revmed.2017.07.005_bib0530","doi-asserted-by":"crossref","first-page":"e10208","DOI":"10.1371\/journal.pone.0010208","article-title":"Predictive features of severe acquired ADAMTS13\u00a0deficiency in idiopathic thrombotic microangiopathies: the French TMA reference center experience","volume":"5","author":"Coppo","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.revmed.2017.07.005_bib0535","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1097\/01.md.0000133622.03370.07","article-title":"Severe ADAMTS13\u00a0deficiency in adult idiopathic thrombotic microangiopathies defines a subset of patients characterized by various autoimmune manifestations, lower platelet count, and mild renal involvement","volume":"83","author":"Coppo","year":"2004","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.revmed.2017.07.005_bib0540","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.revmed.2015.05.003","article-title":"[Management of thrombotic thrombocytopenic purpura in two French centers: a series of 27\u00a0patients]","volume":"37","author":"Deroux","year":"2016","journal-title":"Rev Med Interne"},{"key":"10.1016\/j.revmed.2017.07.005_bib0545","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/BF00858677","article-title":"Treatment of the childhood haemolytic uraemic syndrome with plasma. A multicentre randomized controlled trial. The French Society of Paediatric Nephrology","volume":"2","author":"Loirat","year":"1988","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.revmed.2017.07.005_bib0550","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S0022-3476(88)80071-4","article-title":"Plasma infusion for hemolytic-uremic syndrome in children: results of a multicenter controlled trial","volume":"112","author":"Rizzoni","year":"1988","journal-title":"J Pediatr"},{"key":"10.1016\/j.revmed.2017.07.005_bib0555","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1007\/s00467-008-0964-1","article-title":"Guideline for the investigation and initial therapy of diarrhea-negative hemolytic uremic syndrome","volume":"24","author":"Ariceta","year":"2009","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.revmed.2017.07.005_bib0560","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1007\/s00467-014-2817-4","article-title":"An audit analysis of a guideline for the investigation and initial therapy of diarrhea negative (atypical) hemolytic uremic syndrome","volume":"29","author":"Johnson","year":"2014","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.revmed.2017.07.005_bib0565","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.revmed.2014.10.364","article-title":"[The revolution of monoclonal antibodies in the treatment of thrombotic microangiopathy]","volume":"36","author":"Sauv\u00e8tre","year":"2015","journal-title":"Rev Med Interne"},{"key":"10.1016\/j.revmed.2017.07.005_bib0570","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1056\/NEJMoa1208981","article-title":"Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome","volume":"368","author":"Legendre","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.revmed.2017.07.005_bib0575","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1038\/ki.2014.423","article-title":"Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2\u00a0studies","volume":"87","author":"Licht","year":"2015","journal-title":"Kidney Int"},{"key":"10.1016\/j.revmed.2017.07.005_bib0580","doi-asserted-by":"crossref","first-page":"3337","DOI":"10.1111\/j.1600-6143.2012.04252.x","article-title":"Eculizumab for atypical hemolytic uremic syndrome recurrence in renal transplantation","volume":"12","author":"Zuber","year":"2012","journal-title":"Am J Transplant"},{"key":"10.1016\/j.revmed.2017.07.005_bib0585","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1055\/s-0030-1262885","article-title":"Anti-factor Hautoantibody-associated hemolytic uremic syndrome: review of literature of the autoimmune form of HUS","volume":"36","author":"Dragon-Durey","year":"2010","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.revmed.2017.07.005_bib0590","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1038\/ki.2013.373","article-title":"Prompt plasma exchanges and immunosuppressive treatment improves the outcomes of anti-factor H autoantibody-associated hemolytic uremic syndrome in children","volume":"85","author":"Sinha","year":"2014","journal-title":"Kidney Int"},{"key":"10.1016\/j.revmed.2017.07.005_bib0595","doi-asserted-by":"crossref","first-page":"407","DOI":"10.2215\/CJN.01260212","article-title":"Complement factor H-related protein 1\u00a0deficiency and factor H antibodies in pediatric patients with atypical hemolytic uremic syndrome","volume":"8","author":"Hofer","year":"2013","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.revmed.2017.07.005_bib0600","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1111\/ped.12469","article-title":"Autoimmune-type atypical hemolytic uremic syndrome treated with eculizumab as first-line therapy","volume":"57","author":"Hisano","year":"2015","journal-title":"Pediatr Int"},{"key":"10.1016\/j.revmed.2017.07.005_bib0605","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1007\/s00467-013-2729-8","article-title":"Therapy for patients with antibodies to complement factor H associated HUS","volume":"29","author":"Bagga","year":"2014","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.revmed.2017.07.005_bib0610","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s00467-013-2558-9","article-title":"Long-term remission of atypical HUS with anti-factor H antibodies after cyclophosphamide pulses","volume":"29","author":"Sana","year":"2014","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.revmed.2017.07.005_bib0615","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s00467-013-2722-2","article-title":"Liver-kidney transplantation to cure atypical HUS: still an option post-eculizumab?","volume":"29","author":"Saland","year":"2014","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.revmed.2017.07.005_bib0310","doi-asserted-by":"crossref","first-page":"201","DOI":"10.2215\/CJN.02170508","article-title":"Successful split liver-kidney transplant for factor H associated hemolytic uremic syndrome","volume":"4","author":"Saland","year":"2009","journal-title":"Clin J Am Soc Nephrol"}],"container-title":["La Revue de M\u00e9decine Interne"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S024886631730601X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S024886631730601X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T16:38:43Z","timestamp":1759336723000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S024886631730601X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":62,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["S024886631730601X"],"URL":"https:\/\/doi.org\/10.1016\/j.revmed.2017.07.005","relation":{},"ISSN":["0248-8663"],"issn-type":[{"type":"print","value":"0248-8663"}],"subject":[],"published":{"date-parts":[[2017,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Syndromes h\u00e9molytiques et ur\u00e9miques (SHU) et syndromes de microangiopathie thrombotique apparent\u00e9s\u00a0: traitement et pronostic","name":"articletitle","label":"Article Title"},{"value":"La Revue de M\u00e9decine Interne","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.revmed.2017.07.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Soci\u00e9t\u00e9 Nationale Fran\u00e7aise de M\u00e9decine Interne (SNFMI). Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}